BIOVF OTC
Swedish Orphan Biovitrum AB (publ)
1W: -10.9%
1M: -10.9%
3M: -10.6%
YTD: +21.7%
1Y: +42.8%
3Y: +113.7%
$42.90
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
$8.5B
+15.6% ▲
5Y CAGR: +10.4%
Capital Expenditures
$40M
+98.7% ▲
5Y CAGR: -59.9%
Free Cash Flow
$8.5B
+94.0% ▲
5Y CAGR: +44.2%
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
$93M
-60.8% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $3.3B | $3.3B | $3.0B | $4.4B | $477M |
| Depreciation & Amort. | $2.0B | $2.4B | $3.2B | $3.7B | $10.1B |
| Stock-Based Comp. | $154M | $268M | $0 | $0 | $0 |
| Change in Working Capital | $1.1B | -$806M | -$1.2B | -$179M | -$507M |
| Other Non-Cash Items | -$945M | -$269M | -$524M | -$519M | -$1.5B |
| Operating Cash Flow | $5.5B | $4.7B | $4.5B | $7.4B | $8.5B |
| — Investing Activities — | |||||
| Capital Expenditures | -$370M | -$1.5B | -$407M | -$170M | -$3.1B |
| Acquisitions (Net) | $3M | $0 | -$17.0B | $0 | $0 |
| Investment Purchases | $0 | $0 | $0 | $0 | -$1.0B |
| Investment Sales | $0 | $0 | $0 | $0 | $0 |
| Other Investing | -$320M | -$1.4B | -$4.5B | -$2.9B | -$96M |
| Investing Cash Flow | -$367M | -$1.5B | -$21.9B | -$3.1B | -$4.3B |
| — Financing Activities — | |||||
| Net Debt Issuance | -$4.0B | -$2.4B | $11.2B | -$4.4B | -$4.9B |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$476M | -$572M | -$365M | $8M | $364M |
| Financing Cash Flow | -$4.5B | -$3.0B | $17.0B | -$4.0B | -$4.3B |
| Net Change in Cash | $641M | $316M | -$457M | $236M | $93M |
| Cash End of Period | $1.0B | $1.4B | $904M | $1.1B | $1.0B |
| Free Cash Flow | $5.1B | $3.2B | -$473M | $4.4B | $8.5B |